TITLE

Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors

AUTHOR(S)
Kumano, Masafumi; Miyake, Hideaki; Harada, Ken-ichi; Fujisawa, Masato
PUB. DATE
December 2013
SOURCE
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
92576495

 

Related Articles

  • Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report.  // Journal of Medical Case Reports;2012, Vol. 6 Issue 1, p115 

    The article presents case report a 43-year-old man with advanced chromophobe renal cell carcinoma. The patient was first treated with the tyrosine kinase inhibitor sunitinib and then with sorafenib and the mammalian target of the rapamycin inhibitor everolimus. It is informed that this is the...

  • Temsirolimus.  // Reactions Weekly;Jun2014, Vol. 1507 Issue 1, p29 

    An abstract of the article "Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors," by S. Weikert and colleagues is presented.

  • Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. Voog, Eric; Campillo‐Gimenez, Boris; Elkouri, Claude; Priou, Franck; Rolland, Frederic; Laguerre, Brigitte; Elhannani, Chaza; Merrer, Jacques; Pfister, Christian; Sevin, Emmanuel; L'Haridon, Tifenn; Hasbini, Ali; Moise, Laura; Le Rol, Annick; Malhaire, Jean Pierre; Delva, Remy; Vauléon, Elodie; Cojocarasu, Oana; Deguiral, Philippe; Cumin, Isabelle // International Journal of Cancer;Mar2020, Vol. 146 Issue 6, p1643 

    The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of the context of a clinical trial, the treatments are used sequentially. We...

  • Targeted Therapies.  // Current Medical Literature: Kidney Cancer;Dec2010, Vol. 2 Issue 4, p119 

    The article reviews the articles related to targeted therapies for kidney cancer including "Update on systemic therapies of metastatic renal cell carcinoma," "Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma," and "Pazopanib: an oral multitargeted...

  • Renal Cancer. Blick, Christopher; Herndon, Anthony; Masaarane, Mohammad // Current Medical Literature: Urology;2011, Vol. 17 Issue 2, p51 

    The article addresses the importance of cytoreductive nephrectomy (CN) in improving survival of patients with metastatic renal cell carcinoma after a targeted therapy. The inclusion of little-molecule inhibitors like tyrosine kinase and mammalian target of rapamycin inhibitors have complemented...

  • Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.  // Current Medical Literature: Kidney Cancer;Mar2011, Vol. 3 Issue 1, p31 

    The article discusses a Juvenile Renal Cell Carcinoma (RCC) network study on the effect of mammalian target of rapamycin (mTOR) and tyrosine kinase inhibitors on Xp11 translocation RCC. Patients who had received metastatic disease treatment administered first to fourth-line treatments, which...

  • Temsirolimus.  // Reactions Weekly;Jun2014, Vol. 1506 Issue 1, p26 

    An abstract of the article "Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma," by K. Numakura and colleagues is presented.

  • RAD001 maintained extension of PFS in renal cell carcinoma.  // Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p15 

    The article presents findings of a phase-3 trial of the efficacy of oral mammalian target of rapamycin (mTOR) inhibitor RAD001 in patients with metastatic renal cell carcinoma.

  • Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. Molina, Ana; Ginsberg, Michelle; Motzer, Robert; Molina, Ana M; Ginsberg, Michelle S; Motzer, Robert J // Medical Oncology;Dec2011, Vol. 28 Issue 4, p1527 

    A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of...

  • Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. Tykodi, S. S.; Voong, L. N.; Warren, E. H. // Bone Marrow Transplantation;Aug2010, Vol. 45 Issue 8, p1360 

    A letter to the editor is presented which discusses the author's view on the effect of a combination between allogeneic immunotherapy and mammalian target of rapamycin kinase (mTOR) inhibitor to patients with renal cell carcinoma.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics